Rapid effects of aldosterone on vascular cells: Clinical implications

Steroids

Volumn 69, Issue 8-9, 2004, Pages 575-578

  Lösel, Ralf ^a   Schultz, Armin ^a   Boldyreff, Brigitte ^a   Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Aldosterone; Clinical trial; Mineralocorticoid; Nongenomic effect; Spironolactone; Steroid

Indexed keywords

ALDOSTERONE; BIOLOGICAL MARKER; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPLERENONE; INOSITOL TRISPHOSPHATE; MIFEPRISTONE; NEOMYCIN; RU846; SPIRONOLACTONE; TRANSCRIPTION FACTOR; TYROSINE;

ADRENERGIC SYSTEM; ALKALINIZATION; ARTERY CONSTRICTION; ARTERY RESISTANCE; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CHO CELL; CONFERENCE PAPER; ENDOTHELIUM CELL; FIBROBLAST; GENE INDUCTION; GENOME; HEART MUSCLE CELL; HORMONE ACTION; HUMAN; HYPERALDOSTERONISM; KIDNEY; MODULATION; NEPHRON; NONHUMAN; PREVALENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; SYSTEMIC VASCULAR RESISTANCE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; ENDOTHELIAL CELLS; HUMANS; PHOSPHORYLATION; RECEPTORS, MINERALOCORTICOID; SPIRONOLACTONE; VASCULAR RESISTANCE;

EID: 3543008992     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2004.05.005     Document Type: Conference Paper

References (23)

1. Rossol-Haseroth K., Zhou Q., Braun S., Boldyreff B., Falkenstein E., Wehling M., et al. Mineralocorticoid receptor antagonists do not block rapid ERK activation by aldosterone. Biochem. Biophys. Res. Commun. 318:2004;281-288
2. Calhoun D.A., Nishizaka M.K., Zaman M.A., Thakkar R.B., Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 40:2002;892-896
3. Young W.F. Jr. Minireview: primary aldosteronism-changing concepts in diagnosis and treatment. Endocrinology. 144:2003;2208-2213
4. Silvestre J.S., Robert V., Heymes C., Aupetit-Faisant B., Mouas C., Moalic J.M., et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J. Biol. Chem. 273:1998;4883-4891
5. Takeda Y., Miyamori I., Yoneda T., Iki K., Hatakeyama H., Blair I.A., et al. Production of aldosterone in isolated rat blood vessels. Hypertension. 25:1995;170-173
6. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341:1999;709-717
7. Spertus J.A., Tooley J., Jones P., Poston C., Mahoney E., Deedwania P., et al. Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). Am. Heart J. 143:2002;636-642
8. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348:2003;1309-1321
9. Greene E.L., Kren S., Hostetter T.H. Role of aldosterone in the remnant kidney model in the rat. J. Clin. Invest. 98:1996;1063-1068
10. Lösel R.M., Falkenstein E., Feuring M., Schultz A., Tillmann H.C., Rossol-Haseroth K., et al. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev. 83:2003;965-1016
11. Köppel H., Christ M., Yard B.A., Baer P.C., van der Woude F.J., Wehling M. Nongenomic effects of aldosterone on human renal cells. J Clin Endocrinol Metab. 88:2003;1297-1302
12. +-exchange in MDCK cells by aldosterone involves MAP-kinase ERK1/2. Pflugers Arch. 441:2001;781-786
13. Gekle M., Freudinger R., Mildenberger S., Silbernagl S. Aldosterone interaction with epidermal growth factor receptor signaling in MDCK cells. Am J Physiol Renal Physiol. 282:2002;F669-679
14. Krug A.W., Schuster C., Gassner B., Freudinger R., Mildenberger S., Troppmair J., et al. Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling. J Biol Chem. 277:2002;45892-45897
15. Kellner M., Peiter A., Hafner M., Feuring M., Christ M., Wehling M., et al. Early aldosterone up-regulated genes: new pathways for renal disease? Kidney Int. 64:2003;1199-1207
16. Barbato J.C., Mulrow P.J., Shapiro J.I., Franco-Saenz R. Rapid effects of aldosterone and spironolactone in the isolated working rat heart. Hypertension. 40:2002;130-135
17. Wehling M., Spes C.H., Win N., Janson C.P., Schmidt B.M., Theisen K., Christ M. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab. 83:1998;3517-3522
18. Gunaruwan P., Schmitt M., Taylor J., Lee L., Struthers A., Frenneaux M. Lack of rapid aldosterone effects on forearm resistance vasculature in health. J Renin Angiotensin Aldosterone Syst. 3:2002;123-125
19. Romagni P., Rossi F., Guerrini L., Quirini C., Santiemma V. Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis. 166:2003;345-349
20. Schmidt B.M., Schmieder R.E. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens. 16:2003;80-86
21. Arima S., Kohagura K., Xu H.L., Sugawara A., Abe T., Satoh F., et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol. 14:2003;2255-2263
22. Zhu Y., Rice C.D., Pang Y., Pace M., Thomas P. Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc Natl Acad Sci USA. 100:2003;2231-2236
23. Zhu Y., Bond J., Thomas P. Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci USA. 100:2003;2237-2242